In a landmark regulatory shift, President Donald Trump’s Department of Justice has rescinded dozens of pending and projected rules, dismantling longstanding DEA obstacles to medical cannabis research. The decisive move, announced September 15, strips away the procedural shields that allowed the DEA to delay legitimate marijuana science, notably for FDA-authorized clinical trials targeting Huntington’s disease
In a landmark regulatory shift, President Donald Trump’s Department of Justice has rescinded dozens of pending and projected rules, dismantling longstanding DEA obstacles to medical cannabis research. The decisive move, announced September 15, strips away the procedural shields that allowed the DEA to delay legitimate marijuana science, notably for FDA-authorized clinical trials targeting Huntington’s disease and Multiple Sclerosis.
MMJ International Holdings and subsidiaries, leading advocates for pharmaceutical-grade cannabis research, now await decisive action from DEA Administrator Terrance “Terry” Cole, who must approve—or further stall—their licenses under a Supreme Court mandate. “There are no more excuses,” stated MMJ CEO Duane Boise. “Administrator Cole can approve our registration today and let science move forward.”
The executive order not only exposes the DEA’s years of inaction, but puts thousands of patients in the balance, as the agency’s tribunal system itself was recently labeled unconstitutional. Read the full story at ACCESS Newswire.
